BVAC-C is under clinical development by Cellid and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BVAC-C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BVAC-C is under development for the treatment of human papilloma virus (HPV) type 16 or 18 positive cervical cancer. It is administered as an intravenous injection. It is a immunotherapeutic vaccine using B-cell and monocytes as antigen presenting cell. The drug candidate acts by targeting human papilloma virus protein E7/E6.
Cellid develops innovative immunotherapeutic vaccines, immunology and molecular biology technology, and other related products. The company is headquartered in Seoul, South Korea.
For a complete picture of BVAC-C’s drug-specific PTSR and LoA scores, buy the report here.